10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.

ABSTRACT:

SUBMITTER: DiNardo CD 

PROVIDER: S-EPMC7549397 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature